文献速递白血病

儿童初诊急性淋巴细胞白血病中利妥昔单抗的给药

Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2023-08-05

研究纳入初诊B-ALL儿童及青少年,随机分为诱导治疗中接受或不接受利妥昔单抗(第3天或第6、24天给药)。35例接受利妥昔单抗者中16例(45.7%)发生≥2级输注反应;两组培门冬酶过敏反应、抗培门冬酶抗体及胰腺炎发生率均无显著差异;第8天CD20表达显著降低,但第8、15天及诱导结束时的MRD无差异。

要点

  • 35例接受利妥昔单抗者中16例(45.7%)发生≥2级输注反应。
  • 利妥昔单抗组与非利妥昔单抗组培门冬酶过敏反应、抗培门冬酶抗体、胰腺炎发生率均无显著差异。
  • 利妥昔单抗组第8天CD20表达显著降低,但第8、15天及诱导结束时MRD无差异。

核心结论

  • 儿童B-ALL诱导治疗中给予利妥昔单抗与高输注反应发生率相关,且未显著降低培门冬酶过敏反应、抗培门冬酶抗体或MRD。

研究设计与样本

  • 圣犹达Total XVII研究中的儿童及青少年(1-18岁)初诊B-ALL患者,随机分为诱导治疗中接受或不接受利妥昔单抗(队列1第3天给药,队列2第6天和第24天给药)。
  • 35例接受利妥昔单抗,37例未接受。

主要发现

  • 35例接受利妥昔单抗的患者中,16例(45.7%)发生≥2级利妥昔单抗反应。
  • 接受与未接受利妥昔单抗的患者在培门冬酶反应发生率(P > 0.999)、抗培门冬酶抗体(P = 0.327)及胰腺炎(P = 0.480)方面均无差异。
  • 利妥昔单抗组第8天CD20表达显著降低(P < 0.001),但第8天、第15天及诱导结束时MRD水平无差异。

关键数值与推荐

  • 35例接受利妥昔单抗的患者中16例(45.7%)发生≥2级反应。
  • 培门冬酶反应发生率比较P > 0.999;抗培门冬酶抗体比较P = 0.327;胰腺炎比较P = 0.480。
  • 第8天CD20表达比较P < 0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polyethylene glycol (PEG)-asparaginase (pegaspargase) is a key agent in chemotherapy for acute lymphoblastic leukemia (ALL), but recipients frequently experience allergic reactions. We hypothesized that by decreasing antibody-producing CD20-positive B cells, rituximab may reduce these reactions. Children and adolescents (aged 1-18 years) with newly diagnosed B-ALL treated on the St. Jude Total XVII study were randomized to induction therapy with or without rituximab on day 3 (cohort 1) or on days 6 and 24 (cohort 2). Patient clinical demographics, CD20 expression, minimal residual disease (MRD), rituximab reactions, pegaspargase allergy, anti-pegaspargase antibodies, and pancreatitis were evaluated. Thirty-five patients received rituximab and 37 did not. Among the 35 recipients, 16 (45.7%) experienced a grade 2 or higher reaction to rituximab. There were no differences between recipients and non-recipients in the incidence of pegaspargase reactions (P > 0.999), anti-pegaspargase antibodies (P = 0.327), or pancreatitis (P = 0.480). CD20 expression on day 8 was significantly lower in rituximab recipients (P < 0.001), but there were no differences in MRD levels on day 8, 15, or at the end of induction. Rituximab administration during induction in pediatric patients with B-ALL was associated with a high incidence of infusion reactions with no significant decrease in pegaspargase allergies, anti-pegaspargase antibodies, or MRD.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hoshitsuki K, Zhou Y, Miller AM, et al. Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2023. PMID: 37543655. doi:10.1038/s41375-023-01992-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。